Feb. 20 at 7:05 PM
$TXTM Near-Term Price Prediction (Next 3-6 Months)
Assuming Deloitte confirmation hits via a PR or filing, OTC biotechs with “validation” news often see 300-500% gains in weeks due to FOMO buying, thin liquidity, and social media hype (as seen in similar plays like
$HEMP or early CBD stocks).
• Base Case:
$0.02-
$0.03 (200-300% upside from current). Market cap ~
$175M-
$265M. This prices in initial excitement but fades if no follow-through revenues.
• Bull Case:
$0.04-
$0.05 (500-600% upside) if confirmation coincides with uplist filing or partnership revenue announcements. Market cap ~
$350M-
$440M.
• Bear Case: Stays sub-
$0.01 if confirmation is underwhelming (e.g., partial validation) or market dumps on profit-taking.